David J Sperbeck, PHD in Anchorage, AL - Psychologist

David J Sperbeck, PHD is a Psychologist based in Anchorage, Alabama. David J Sperbeck is licensed to practice in Alaska (license number 233) and his current practice location is 2530 Debarr Road, Anchorage, Alabama. He can be reached at his office (for appointments etc.) via phone at (907) 563-8816.

NPI number for David J Sperbeck is 1841397114 and his current mailing address is 2530 Debarr Road, Anchorage, Alabama. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1841397114.

Contact Information

	David J Sperbeck, PHD
	2530 Debarr Road, Anchorage, AL 99508
	(907) 563-8816
	(907) 264-4331

Healthcare Provider's Profile

Full Name	David J Sperbeck
Gender	Male
Speciality	Psychologist
Location	2530 Debarr Road, Anchorage, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1841397114
Provider Enumeration Date: 09/20/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for David J Sperbeck such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1841397114	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103T00000X	Psychologist	233 (Alaska)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. David J Sperbeck is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
David J Sperbeck, PHD 2530 Debarr Road, Anchorage, AL 99508 Ph: (907) 563-8816	David J Sperbeck, PHD 2530 Debarr Road, Anchorage, AL 99508 Ph: (907) 563-8816

News Archive

Predicting treatment responses earlier for brain tumor patients

Using metabolic or molecular imaging to measure brain tumor patients' response to treatment is a powerful predictor of survival, notes a first-of-its-kind study presented at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

ISU entomologist urges summertime precautions against mosquitoes and ticks

Ryan Smith, an assistant professor of entomology at Iowa State University is encouraging Iowans to take precautions this summer when spending time outdoors in areas commonly populated by mosquitoes and ticks, which can transmit West Nile virus and other diseases that can have serious or potentially fatal outcomes.

Successful treatments help HIV-infected persons achieve similar longevity as those without HIV

New research from the Johns Hopkins Bloomberg School of Public Health suggests that HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV.

Toshiba receives top ratings on IMV ServiceTrak's 2010 MRI system service report

As healthcare organizations continue to look for the best value in imaging and customer service, Toshiba America Medical Systems, Inc.'s Service organization continues to deliver on the company's dedication to top-tier service and customer satisfaction. In the 2010 IMV ServiceTrak™ ratings report on MRI system service, Toshiba received more number one ratings than any other manufacturer in the categories of Service Performance, Phone Support Performance and Remote Service.

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

David J Sperbeck, PHD - Psychologist in Anchorage, AL